Gillis W. Long Hansen's Disease Center at Louisiana State University, US Public Health Service, PO Box 25072, Baton Rouge, LA 70894-5072, USA
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Sultamicillin, a highly stable, orally active double ester of ampicillin/sulbactam (1.5:1, w/w), is available from Pfizer Central Research, as a tosylate salt. In the present study we tested the effect of the compound on the growth of M. leprae in mice, by administering the drug by the `continuous' method for 6 months, and by the `kinetic' method where the drug is given for a short period of time and then discontinued. 4 The results showed that oral ampicillin/sulbactam was bactericidal to M. leprae. (The terms `continuous' and `kinetic' in drug trials against M. lepraein mouse foot pads were introduced by Shepard 4 in 1965, and have been generally used since then.)
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
M. leprae harvested from foot pads of BALB/c or nu/numice was used in the experiments. The bacteria, originally derived from a patient, have been maintained by serial passages in mouse foot pads. In one experiment, M. lepraefrom nu/numice was inoculated (1 x 10 4/0.03 mL/foot pad) into both hind foot pads of 20 BALB/c mice (10 control, 10 experimental). In another experiment, the bacteria (harvested from BALB/c foot pads) were inoculated into the foot pads of 20 `normal' littermates of beige (C57BL bg/bg) mice (10 control, 10 experimental). These mice were used only because of their availability at the time. The strain of mice or the source of inoculum apparently made little difference in these experiments. The bacteria multiply to about 1 x 10 6/foot pad in approximately 6 months; if the animals are maintained for longer periods, the number of bacteria/foot pad might increase for about 3 or 4 months, and then decline. To evaluate the bactericidal action of ampicillin/sulbactam, 60 BALB/c mice were inoculated with M. lepraederived from foot pads of BALB/c mice (30 control, 30 experimental).
Treatment
Sultamicillin tosylate dihydrate (purity: 73.3% as ampicillin/sulbactam) was generously supplied by Pfizer Central Research. In the `continuous' method of drug administration, three concentrations of the drug were tested: 0.01% and 0.10% in littermates of bg/bg mice and 0.20% in BALB/c mice. Because there was no previous experience in using oral ampicillin/sulbactam against M. leprae, the concentrations used were chosen arbitrarily; the results showed that they worked. The drug was mixed with ground mouse chow, fresh mixtures being prepared once a week. Animals in the control groups received regular ground mouse chow. The feed was changed in the cages twice a week. Water and feed were provided ad libitum. The animals were killed by CO2 asphyxiation at approximately 6 months, when growth of M. leprae was detected in the untreated controls, by periodic monitoring. The bacteria in the foot pads of six mice in each group were counted by the method of Shepard & McRae. 5 For bacterial enumeration, the hind foot pad tissues of each mouse were pooled before homogenizing.The results are presented as means (± S.D.). Significance of the difference between each control and experimental group was determined by Student's unpaired t-test. A Pvalue of <0.05 was considered significant.
In the `kinetic' experiment to determine whether the drug was bactericidal, it was mixed with the feed at a concentration of 0.50%. Treatment was started 2 months after inoculation of the mice with M. leprae, when the bacteria were in the logarithmic phase of growth. Drug administration was stopped after 3 months. Three mice from the treated and the control groups were killed every month for the next 8 months, and the acid-fast bacteria in the foot pads of individual mice were enumerated. Mean values of the three counts for each month are given in the results. The animals showed no adverse effects such as emaciation or loss of hair.
![]() |
Results and discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
As seen in Figure 1, `continuous' administration of oral ampicillin/sulbactam suppressed growth of the bacteria in both strains of mice used. For the three different drug concentrations used, 0.01% resulted in a growth inhibition of 54% (P< 0.005); 0.10% in inhibition of 74% (P< 0.0005); 0.20% in inhibition of 93% (P<0.0005). In the `kinetic' method, where drug administration was discontinued after 3 months of treatment, multiplication of the bacteria, compared with the controls, continued to be inhibited by the drug (Figure 2). The results indicated a bactericidal effect of the drug on the bacteria. 4 According to this procedure, if the bacteria in the treated group do not grow to the level of the controls in 3 months after discontinuation of treatment, the drug is considered bactericidal.
|
|
Multidrug treatment of leprosy has been adopted since 1980 for the `elimination' of the disease as a public health problem by the year 2000. However, the ability of bacteria to develop multidrug resistance has been known for over three decades. Multidrug resistance of M. leprae has been reported before, 9 and sporadic reports of relapses after multidrug treatment of leprosy continue to appear, although on a small scale. Multidrug-resistant tuberculosis has become a major problem in many developing countries, and in Russia, in recent years. Mycobacterial ß-lactamase is not a metallo-enzyme (metallo-enzymes are highly resistant to inhibitors), and inhibitor-resistant ß-lactamases have not been reported in mycobacteria. We have shown earlier that injectable ampicillin/sulbactam suppressed the growth of several species of cultivable mycobacteria in vitro, and that the drug was bactericidal to M. tuberculosisH37Rv. 10 Results of the present study demonstrate that oral ampicillin/sulbactam is bactericidal to M. leprae, as was reported before for injectable ampicillin/sulbactam, 3 in similar studies.
Sulbactam inhibits chromosomal ß-lactamase more effectively than clavulanate; 1 in our studies by the BACTEC method, the MIC of sulbactam for M. tuberculosisH37Rv was 9.38 mg/L, while that of clavulanate was 31.25 mg/L, indicating that sulbactam is more active than clavulanate in the system. 10 Orally administered ampicillin/sulbactam is readily absorbed, and hydrolysed to release ampicillin in the body. The compound would probably be useful as a rational antimicrobial agent to treat mycobacterial infections resistant to other drugs.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 . Prabhakaran, K., Harris, E. B., Randhawa, B. & Hastings, R. C. (1992). Reversal of drug resistance in Mycobacterium leprae by ampicillin/sulbactam. Microbios 72,137 42.[ISI][Medline]
3 . Randhawa, B., Harris, E. B., Prabhakaran, K. & Hastings, R. C. (1994). Bactericidal action of ampicillin/sulbactam against Mycobacterium leprae. Journal of Antimicrobial Chemotherapy 33, 10357.[ISI][Medline]
4 . Shepard, C. C. (1965). A kinetic method for the study of activity of drugs against Mycobacterium leprae in mice. International Journal of Leprosy 33, 42935.
5 . Shepard, C. C. & McRae, D. H. (1968). A method for counting acid-fast bacteria. International Journal of Leprosy 36, 7882.
6 . Gelber, R. H. (1991). The activity of amoxicillin plus clavulanic acid against Mycobacterium lepraein mice. Journal of Infectious Diseases 163, 13747.[ISI][Medline]
7 . Nadler, J. P., Berger, J., Nord, J. A., Cofsky, R. & Saxena, M. (1991). Amoxicillinclavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99, 10256.[Abstract]
8 . Chambers, H. F., Kocagoz, T., Sipit, T., Turner, J. & Hopewell, P. C. (1998). Activity of amoxicillin/clavulanate in patients with tuberculosis. Clinical Infectious Diseases 26, 8747.[ISI][Medline]
9 . Jacobson, R. R. (1985). Treatment. In Leprosy (Hastings, R. C., Ed.), pp. 193222. Churchill Livingstone, Edinburgh, UK.
10 . Prabhakaran, K., Harris, E. B., Randhawa, B, Adams, L. B., Williams, D. L. & Hastings, R. C. (1993). Use of ß-lactam/ß-lactamase-inhibitor combinations as antimycobacterial agents. Microbios 76, 25161.[ISI][Medline]
Received 3 November 1998; returned 26 February 1999; revised 8 March 1999; accepted 29 March 1999